NASDAQ:APLT

Applied Therapeutics Competitors

Add
Compare
Today's Range N/A
50-Day Range
$16.36
MA: $19.60
$23.72
52-Week Range N/A
Volume94,087 shs
Average Volume131,258 shs
Market Capitalization$439.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27

Competitors

Applied Therapeutics (NASDAQ:APLT) Vs. AMTI, CYTK, FGEN, SAVA, ADCT, and MYOV

Should you be buying APLT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Applied Therapeutics, including Applied Molecular Transport (AMTI), Cytokinetics (CYTK), FibroGen (FGEN), Cassava Sciences (SAVA), ADC Therapeutics (ADCT), and Myovant Sciences (MYOV).

Applied Therapeutics (NASDAQ:APLT) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Applied Molecular Transport's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Applied Molecular Transport, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00403.00
Applied Molecular Transport00403.00

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Applied Molecular Transport has a consensus target price of $68.75, indicating a potential upside of 40.51%. Given Applied Therapeutics' higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Applied Molecular Transport.

Profitability

This table compares Applied Therapeutics and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
Applied Molecular TransportN/AN/AN/A

Applied Therapeutics (NASDAQ:APLT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Cytokinetics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A
Cytokinetics$26.87 million63.94$-121,690,000.00($2.11)-11.45

Applied Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Cytokinetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00403.00
Cytokinetics011002.91

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Cytokinetics has a consensus target price of $33.6364, indicating a potential upside of 39.22%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Cytokinetics.

Profitability

This table compares Applied Therapeutics and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
Cytokinetics-209.88%-3,065.14%-36.39%

Summary

Applied Therapeutics beats Cytokinetics on 7 of the 13 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 3.4% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and FibroGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A
FibroGen$256.58 million6.63$-76,970,000.00($0.89)-20.87

Applied Therapeutics has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and FibroGen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00403.00
FibroGen15202.13

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. FibroGen has a consensus target price of $45.8333, indicating a potential upside of 146.81%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than FibroGen.

Profitability

This table compares Applied Therapeutics and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
FibroGen-191.78%-48.19%-27.72%

Summary

Applied Therapeutics beats FibroGen on 7 of the 13 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Cassava Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-153.96

Cassava Sciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Cassava Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00403.00
Cassava Sciences00403.00

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 15.00%. Given Applied Therapeutics' higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Cassava Sciences.

Profitability

This table compares Applied Therapeutics and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
Cassava SciencesN/A-22.01%-20.85%

Summary

Cassava Sciences beats Applied Therapeutics on 5 of the 9 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and ADC Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00403.00
ADC Therapeutics01402.80

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. ADC Therapeutics has a consensus target price of $47.50, indicating a potential upside of 98.00%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than ADC Therapeutics.

Profitability

This table compares Applied Therapeutics and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
ADC TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Applied Therapeutics and ADC Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A
ADC Therapeutics$2.34 million706.29$-116,480,000.00($2.36)-10.17

Applied Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Applied Therapeutics beats ADC Therapeutics on 6 of the 10 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 54.3% of Applied Therapeutics shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by company insiders. Comparatively, 31.5% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Myovant Sciences and Applied Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
Applied Therapeutics00403.00

Myovant Sciences currently has a consensus price target of $31.1667, indicating a potential upside of 71.72%. Applied Therapeutics has a consensus price target of $56.00, indicating a potential upside of ∞. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Myovant Sciences.

Profitability

This table compares Myovant Sciences and Applied Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
Applied TherapeuticsN/A-85.39%-70.42%

Volatility & Risk

Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Myovant Sciences and Applied Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-5.39
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)N/A

Myovant Sciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Applied Therapeutics beats Myovant Sciences on 8 of the 11 factors compared between the two stocks.


Applied Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93flat$1.72 billionN/A0.00Insider Buying
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16flat$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57flat$1.70 billion$256.58 million-7.11Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57flat$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99flat$1.65 billion$2.34 million-10.17
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15flat$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26flat$1.64 billionN/A0.00Insider Selling
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19flat$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80flat$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32flat$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61flat$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41flat$1.54 billionN/A0.00Insider Selling
Generation Bio logo
GBIO
Generation Bio
1.8$27.20flat$1.53 billionN/A0.00Insider Selling
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28flat$1.53 billionN/A0.00Lockup Expiration
Gap Down
uniQure logo
QURE
uniQure
1.7$33.74flat$1.52 billion$7.28 million-8.95
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60flat$1.52 billion$145.97 million-6.72News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56flat$1.51 billion$82.27 million-18.44Unusual Options Activity
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96flat$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88flat$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31flat$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30flat$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19flat$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$31.00flat$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20flat$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80flat$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16flat$1.40 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95flat$1.37 billion$73.41 million-4.43
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62flat$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84flat$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80flat$1.31 billionN/A0.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35flat$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51flat$1.26 billion$4.23 million-9.22
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90flat$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69flat$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49flat$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70flat$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39flat$1.18 billion$59.70 million-193.90Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23flat$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58flat$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38flat$1.15 billionN/A-8.88High Trading Volume
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07flat$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54flat$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78flat$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23flat$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81flat$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50flat$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27flat$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42flat$1.07 billion$120,000.00-3.86News Coverage
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57flat$1.07 billionN/A-8.82
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16flat$1.07 billion$1.52 million-11.79News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.